MediciNova, Inc.

Contributing Author

Recent Articles by MediciNova, Inc.

Dec-08	MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND MNOV GlobeNewswire
Dec-01	Message from the CEO to MediciNova Shareholders MNOV GlobeNewswire
Nov-18	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor MNOV GlobeNewswire
Nov-06	MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards MNOV GlobeNewswire
Nov-04	MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MNOV GlobeNewswire
Oct-30	MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication MNOV GlobeNewswire
Oct-06	MediciNova to Present at the LD Micro Main Event XIX Investor Conference MNOV GlobeNewswire
Sep-22	MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) MNOV GlobeNewswire
Sep-16	MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND MNOV GlobeNewswire
Sep-08	MediciNova Provides Shareholder Update on Key Developments MNOV GlobeNewswire
Sep-03	MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference MNOV GlobeNewswire
Aug-26	MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial MNOV GlobeNewswire
Jul-31	MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million MNOV GlobeNewswire
Jul-24	MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials MNOV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.